Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Brigatinib (Alunbrig™)

Last Updated: 02/26/21

Status: Solid Tumor and NF2 Clinical Trial

Chemical Structure, brigatinib

Legal Status:
℞ - Trial
Administered By:
Pill - Oral
Tumor Target:
Solid Tumors; Schwannoma, Meningioma
anaplastic lymphoma kinase (ALK) and
epidermal growth factor receptor (EGFR) inhibitor

Brigatinib (Alunbrig™) is a clinical trial tumor drug treatment listed for solid tumors. Early mouse trial studies suggest brigatinib may have good results with the reduction of size in solid tumors including; schwannoma and meningioma.

During the mouse trials no growth was seen with long treatment breaks, followed by continued size reduction when the treatment continued again later. If this holds for human trials, breaks for healing from possible side effects or for treatments of other health issues.

Treatment Availability

This solid tumor trial is available to individuals with neurofibromatosis type 2 (NF2), or other solid tumors.

Results in the Mouse Trial Phase

In mouse trials with brigatinib tumors reduced in size and remained stable during three (3) month breaks in treatment.

Side Effects

No known side effects at this time except possible kidney or liver failure, like all tumor drug treatments.

Source Information

What is NF2? | About Us | Treatment Options | Sitemap

Site Search

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2021